Drug intelligence / Profile preview

ruvonoflast

Development stage: Phase 2
Lead developer: NodThera
Modality: Small Molecules
Administration: Oral

Overview

**Ruvonoflast (NT-0796)** is a clinical-stage, orally active prodrug that potently and selectively inhibits the NLRP3 inflammasome, a multi-protein complex central to chronic inflammation. Designed for central nervous system (CNS) penetration, it reduces IL-1β release (IC50 0.32 nM in human PBMCs) and targets neuroinflammation and cardiovascular diseases. Developed by NodThera (Essex, UK), it originated from SAR optimization of the known NLRP3 inhibitor CP-456,773, featuring a molecular weight of 409.48 (C23 formula) and (S)-stereochemistry.[1][2][3][5][6]

Other names: (S)-ruvonoflast(S)-NT-0796

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on ruvonoflast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ruvonoflast.

Explore the full profile